论文部分内容阅读
血药浓度安全范围较小、个体差异较大的药物,若血药浓度与疗效毒性间存在密切关系,临床即须进行血浓监测,以便给药方案个体化。设计个体化的给药方案要根据药代动力学(Pharmacokinetics,PK)的个体参数;在研究初期,个体参数尚未测定,治疗只能参考群体参数。病患康复,证明个体参数反映了客观规律;此时个体参数便可汇入群体、充实群体参数。群体特性决定于个体特性,而个体特性又受群体规律的制
Blood concentration less secure, individual differences between the larger drug, if there is a close relationship between plasma concentration and efficacy of toxicity, the clinical need to be blood concentration monitoring, in order to dosing program individualized. Designing individualized dosing regimens is based on individual parameters of Pharmacokinetics (PK); in the early stages of the study, individual parameters have not been determined and treatment can only refer to group parameters. Rehabilitation of patients proves that individual parameters reflect the objective laws. At this time, individual parameters can be imported into the community to enrich group parameters. Group characteristics are determined by the individual characteristics, and individual characteristics are subject to the rules of the community